Jérôme Bédier, CEO of Olon France, attests to the impact of the Eurobiomed network in fostering collaborations among health innovation stakeholders in Southern France.
What are the new prospects for Olon France, formerly GTP Bioways, since its integration into the Olon group?
Since July 2024, GTP Bioways has gained a new dimension by joining the Olon group, a major industrial player with approximately 3000 employees. This integration enables us to offer a comprehensive range of bioproduction services, particularly for monoclonal antibodies and ADCs (Antibody-Drug Conjugates).
Our various sites in France, located in Labège, Toulouse, Saint-Julien-en-Genevois, and Veyron-Monton, are now part of an international dynamic with significant development prospects, such as the increase in our coupling capacity from 100 to 500 liters. The group also provides us with a considerable change of scale, particularly in microbial processes where production capacities are multiplied by 1000.
How does membership in the Eurobiomed community contribute to the growth of your operations?
The robust Eurobiomed network has facilitated the realization of collaborations with several member companies. A public example is our partnership with Abionyx in the Toulouse region. In total, five projects have been initiated with cluster members, encompassing both process development and GMP production.
How is Eurobiomed's regional presence an asset for Olon France?
Eurobiomed's presence across the Mediterranean arc, from Nice to Toulouse, including Marseille and Montpellier, perfectly aligns with our regional network coverage. This proximity facilitates exchanges and the development of collaborative projects. The events organized by the cluster and membership in this common network create an environment conducive to interactions among various health innovation stakeholders. This regional dimension is a true catalyst for the growth of our activities.
